Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) trades at $107.00. Illumina, Inc. Market cap: $17.0B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for ILMNV: ILMNV does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ILMNV against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on ILMNV.
How is this calculated? →Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) Healthcare & Pipeline Overview
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) pioneers genomics solutions, enabling researchers and clinicians to unlock the power of the genome. With a focus on DNA sequencing and array-based technologies, Illumina drives advancements in precision medicine, drug discovery, and agrigenomics, maintaining a strong position in the rapidly evolving life sciences industry.
What Is the Investment Thesis for ILMNV?
Illumina's investment thesis rests on its dominant position in the genomics market and its ability to drive innovation in DNA sequencing technologies. The increasing adoption of NGS in clinical diagnostics and drug development is a key growth driver. With a market capitalization of $17.0B and a beta of 1.20, ILMNV presents a potentially volatile but high-growth opportunity. Upcoming catalysts include the expansion of its clinical sequencing applications and partnerships with pharmaceutical companies. However, potential risks include increased competition and regulatory hurdles in the clinical diagnostics market. Investors should monitor Illumina's revenue growth, gross margins, and R&D spending to assess its long-term value.
Based on FMP financials and quantitative analysis
ILMNV Key Highlights
Illumina's market capitalization stands at $16.99 billion, reflecting its significant presence in the genomics market.
- The company's beta of 1.20 indicates a higher volatility compared to the overall market.
- Illumina's focus on next-generation sequencing (NGS) technologies positions it as a leader in genomic analysis.
- The company's products and services are used in a wide range of applications, including genomic research, drug development, and personalized medicine.
- Illumina's global presence extends to North America, Europe, Asia-Pacific, and Latin America, with a strong presence in key research hubs and clinical centers.
Who Are ILMNV's Competitors?
ILMNV is benchmarked below against 3 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| PACB Pacific Biosciences of California, Inc. | $1.23 | -3.15% | $382M | — |
| TMO Thermo Fisher Scientific Inc. | $629.48 | +2.60% | $234B | 66 |
| AFFX Affymetrix, Inc. | $14.01 | -0.07% | 52 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ILMNV's Key Strengths?
Technological leadership in NGS.
- Established customer base.
- Strong brand reputation.
- Global presence.
What Are ILMNV's Weaknesses?
High cost of sequencing platforms.
- Complexity of NGS workflows.
- Dependence on consumables sales.
- Regulatory hurdles in the clinical diagnostics market.
What Could Drive ILMNV Stock Higher?
Launch of new sequencing platforms with improved accuracy and speed.
- Expansion of clinical sequencing applications in cancer diagnostics and genetic testing.
- Partnerships with pharmaceutical companies to develop NGS-based assays for drug development.
- Increasing adoption of NGS in emerging markets, such as China and India.
What Are the Key Risks for ILMNV?
Increased competition from other genomics companies, such as Pacific Biosciences and Thermo Fisher Scientific.
- Technological obsolescence due to rapid advancements in sequencing technologies.
- Regulatory hurdles in the clinical diagnostics market.
- Economic downturn affecting research funding and healthcare spending.
- Dependence on consumables sales, which can be affected by changes in customer demand.
What Are the Growth Opportunities for ILMNV?
- Expansion of Clinical Sequencing Applications: Illumina has the opportunity to expand the use of its NGS technologies in clinical diagnostics, including cancer screening, genetic testing, and infectious disease detection. The market for clinical sequencing is estimated to reach $20 billion by 2030, driven by increasing awareness of the benefits of personalized medicine and the decreasing cost of sequencing. Illumina can leverage its established customer base and technological expertise to capture a significant share of this market. Timeline: Ongoing.
- Partnerships with Pharmaceutical Companies: Illumina can collaborate with pharmaceutical companies to develop NGS-based assays for drug development and clinical trials. The market for NGS-based drug development tools is estimated to reach $10 billion by 2028, driven by the increasing use of genomics in drug discovery and clinical research. Illumina can leverage its sequencing platforms and bioinformatics capabilities to provide valuable insights to pharmaceutical companies. Timeline: Ongoing.
- Development of New Sequencing Technologies: Illumina can invest in the development of new sequencing technologies that offer improved accuracy, speed, and cost-effectiveness. The market for advanced sequencing technologies is estimated to reach $15 billion by 2027, driven by the increasing demand for high-throughput sequencing in research and clinical applications. Illumina can maintain its technological leadership by developing innovative sequencing platforms that meet the evolving needs of its customers. Timeline: Ongoing.
- Expansion into Emerging Markets: Illumina can expand its presence in emerging markets, such as China and India, where there is a growing demand for genomic analysis in research and clinical diagnostics. The market for NGS technologies in emerging markets is estimated to reach $8 billion by 2026, driven by increasing investments in healthcare and research infrastructure. Illumina can leverage its global presence and established customer base to capture a significant share of this market. Timeline: Ongoing.
- Application in Agrigenomics: Illumina can apply its sequencing technologies to agrigenomics, including crop improvement, livestock breeding, and agricultural biotechnology. Illumina can leverage its sequencing platforms and bioinformatics capabilities to provide valuable insights to agricultural researchers and breeders. Timeline: Ongoing.
What Are ILMNV's Competitive Advantages?
- Technological Leadership: Illumina has a strong technological lead in NGS, with a broad portfolio of patents and proprietary technologies.
- Established Customer Base: Illumina has a large and established customer base, including leading research institutions, clinical laboratories, and pharmaceutical companies.
- High Switching Costs: Customers face high switching costs due to the complexity of NGS workflows and the need for specialized expertise.
- Network Effects: Illumina's sequencing platforms generate a large amount of data, which can be used to improve the accuracy and efficiency of future sequencing runs.
What Does ILMNV Do?
Illumina, Inc. was founded in 1998 with the vision of improving human health by unlocking the power of the genome. The company has evolved from a provider of DNA sequencing technologies to a comprehensive genomics solutions provider. Illumina's products and services are used by researchers, clinicians, and commercial organizations across the globe. Its core technologies include next-generation sequencing (NGS) and array-based solutions, which enable the analysis of genetic variation and biological function. These technologies are applied in a wide range of applications, including genomic research, drug development, personalized medicine, and agrigenomics. Illumina's sequencing platforms are used to sequence entire genomes, identify genetic mutations, and analyze gene expression. The company's array-based solutions are used for genotyping, copy number variation analysis, and methylation profiling. Illumina's geographic reach extends to North America, Europe, Asia-Pacific, and Latin America, with a strong presence in key research hubs and clinical centers. The company faces competition from other genomics companies, as well as from established players in the life sciences industry. Illumina continues to invest in research and development to maintain its technological leadership and expand its product offerings.
What Products and Services Does ILMNV Offer?
- Develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function.
- Offers next-generation sequencing (NGS) platforms for genomic research, drug development, and clinical diagnostics.
- Provides array-based solutions for genotyping, copy number variation analysis, and methylation profiling.
- Supports a wide range of applications, including genomic research, personalized medicine, and agrigenomics.
- Offers bioinformatics tools and services for data analysis and interpretation.
- Provides training and support to customers using its products and services.
- Collaborates with pharmaceutical companies to develop NGS-based assays for drug development and clinical trials.
How Does ILMNV Make Money?
- Sells NGS platforms and array-based solutions to research institutions, clinical laboratories, and commercial organizations.
- Generates revenue from the sale of consumables, such as sequencing reagents and microarrays.
- Provides service and support contracts to customers using its products and services.
- Offers bioinformatics tools and services for data analysis and interpretation.
- Collaborates with pharmaceutical companies to develop NGS-based assays for drug development and clinical trials.
What Industry Does ILMNV Operate In?
Illumina operates in the life sciences tools and services industry, which is experiencing rapid growth driven by advancements in genomics and personalized medicine. The market for NGS technologies is expected to continue to expand, fueled by increasing demand for genomic analysis in research, clinical diagnostics, and drug development. Illumina faces competition from companies such as Pacific Biosciences and Thermo Fisher Scientific, but it maintains a leading position due to its technological innovation and established customer base. The industry is also subject to regulatory scrutiny, particularly in the clinical diagnostics market.
Who Are ILMNV's Key Customers?
- Research institutions conducting genomic research.
- Clinical laboratories performing genetic testing and diagnostics.
- Pharmaceutical companies developing new drugs and therapies.
- Agricultural researchers and breeders working on crop improvement and livestock breeding.
- Government agencies and public health organizations.
Company Profile
Illumina, Inc. Common Stock Ex-distribution When-Issued operates in the Medical - Diagnostics & Research industry within the Healthcare sector. The company is led by CEO Jacob Thaysen.
ILMNV Financials
Bull Case vs Bear Case
Bull Case
- Technological leadership in NGS.
- Established customer base.
- Strong brand reputation.
- Global presence.
Bear Case
- High cost of sequencing platforms.
- Complexity of NGS workflows.
- Dependence on consumables sales.
- Regulatory hurdles in the clinical diagnostics market.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
ILMNV Latest News
No recent news available for ILMNV.
ILMNV Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ILMNV.
Price Targets
Wall Street price target analysis for ILMNV.
ILMNV MoonshotScore
What does this score mean?
The MoonshotScore rates ILMNV 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jacob Thaysen
CEO
Jacob Thaysen brings extensive experience in technology and healthcare to his role as CEO of Illumina. Prior to joining Illumina, he held leadership positions at Agilent Technologies, where he oversaw the company's diagnostics and genomics businesses. His career spans over two decades, with a focus on driving innovation and growth in the life sciences industry. He holds advanced degrees in engineering and business administration, providing a strong foundation for leading a technology-driven company like Illumina.
Track Record: Since assuming the role of CEO, Jacob Thaysen has focused on strengthening Illumina's position as a leader in genomics and driving innovation in DNA sequencing technologies. He has overseen the expansion of Illumina's clinical sequencing applications and partnerships with pharmaceutical companies. Key milestones under his leadership include the launch of new sequencing platforms and the expansion of Illumina's presence in emerging markets.
ILMNV Healthcare Stock FAQ
What does Illumina, Inc. Common Stock Ex-distribution When-Issued do?
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) is a leading developer, manufacturer, and marketer of integrated systems for analyzing genetic variation and biological function. The company's core offerings include next-generation sequencing (NGS) platforms and array-based solutions, which are used by researchers, clinicians, and commercial organizations to unlock the power of the genome.
What do analysts say about ILMNV stock?
Analyst consensus on ILMNV stock reflects a generally positive outlook, driven by Illumina's dominant position in the genomics market and its growth potential in clinical sequencing and drug development. Key valuation metrics include revenue growth, gross margins, and R&D spending. Analysts are closely monitoring Illumina's ability to maintain its technological leadership and expand its market share in emerging markets.
What are the main risks for ILMNV?
The main risks for ILMNV include increased competition from other genomics companies, such as Pacific Biosciences and Thermo Fisher Scientific, which could erode Illumina's market share and pricing power. Technological obsolescence is another risk, as rapid advancements in sequencing technologies could render Illumina's platforms outdated.
What are the key factors to evaluate for ILMNV?
Evaluate ILMNV on fundamentals, analyst consensus, and risk factors. Illumina's investment thesis rests on its dominant position in the genomics market and its ability to drive innovation in DNA sequencing technologies. Not financial advice.
How frequently does ILMNV data refresh on this page?
ILMNV's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ILMNV's recent stock price performance?
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Technological leadership in NGS. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ILMNV overvalued or undervalued right now?
Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ILMNV before investing?
Before investing in Illumina, Inc. Common Stock Ex-distribution When-Issued (ILMNV), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided in this dossier is based on publicly available data and is intended for informational purposes only. It does not constitute investment advice.